Document is current
Any future updates will be listed below
-
Authors
Beaulieu, Elizabeth https://orcid.org/0000-0001-8447-7073
Rittenhouse, Brian
- License Information
-
More Information
Article History
Received: 1 November 2024
Revised: 12 May 2025
Accepted: 19 May 2025
First Online: 11 June 2025
Declarations
:
: Office-based methadone is identified as optimal in a cost-effectiveness analysis against clinic-based methadone and office-based buprenorphine to treat opioid use disorder in a U.S. setting.
: The authors declare no competing interests.
